Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · aacc35a2-0e82-4ba7-bec1-297802d4fa44

Aromasin

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2025-12-24
Captured
2026-09-09T23:37:54.830918+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE AROMASIN is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
Full extracted label fields
application numbers
  1. NDA020753
boxed warning exact
    brand names
    1. Aromasin
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf066b7a-032a-416c-8d40-15ba581423e3
    generic names
    1. EXEMESTANE
    id
    aacc35a2-0e82-4ba7-bec1-297802d4fa44
    indications and usage exact
    1. 1 INDICATIONS AND USAGE AROMASIN is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
    indications and usage tables exact
      is original packager
      1. true
      manufacturer names
      1. Pharmacia & Upjohn Company LLC
      matched search terms
      1. cancer
      package ndcs
      1. 0009-7663-04
      product ndcs
      1. 0009-7663
      product types
      1. HUMAN PRESCRIPTION DRUG
      recent major changes exact
        record type
        complete_spl_indications_section_candidate
        routes
        1. ORAL
        rxcuis
        1. 261317
        2. 310261
        source batch
        file
        /private/tmp/cancer-full-research/indications/raw/labels-00500.json
        meta
        disclaimer
        Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
        last updated
        2026-09-09
        results
        limit
        100
        skip
        500
        total
        830
        sha256
        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
        url
        https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=500&sort=id%3Aasc
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%22aacc35a2-0e82-4ba7-bec1-297802d4fa44%22
        spl effective date
        2025-12-24
        spl effective time
        20251224
        spl set id
        cf066b7a-032a-416c-8d40-15ba581423e3
        spl version
        24
        substance names
        1. EXEMESTANE
        uniis
        1. NY22HMQ4BX
        verification flags
        1. oncology_keyword_candidate_not_clinically_classified
        2. spl_text_not_verified_identical_to_latest_approved_label
        3. individual_indications_not_split_or_reconciled
        Drugs@FDA application source records
        1. application number
          NDA020753
          payload
          all indexed label documents
          1. Appl No
            020753
            Application Docs Date
            1999-10-21 00:00:00
            Application Docs ID
            13341
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            1
            Submission Type
            ORIG
          2. Appl No
            020753
            Application Docs Date
            2003-12-02 00:00:00
            Application Docs ID
            13342
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            3
            Submission Type
            SUPPL
          3. Appl No
            020753
            Application Docs Date
            2004-09-29 00:00:00
            Application Docs ID
            13343
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            5
            Submission Type
            SUPPL
          4. Appl No
            020753
            Application Docs Date
            2005-10-07 00:00:00
            Application Docs ID
            13344
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            6
            Submission Type
            SUPPL
          5. Appl No
            020753
            Application Docs Date
            2011-03-28 00:00:00
            Application Docs ID
            13345
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            9
            Submission Type
            SUPPL
          6. Appl No
            020753
            Application Docs Date
            2011-03-28 00:00:00
            Application Docs ID
            13346
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            11
            Submission Type
            SUPPL
          7. Appl No
            020753
            Application Docs Date
            2011-03-28 00:00:00
            Application Docs ID
            13347
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            12
            Submission Type
            SUPPL
          8. Appl No
            020753
            Application Docs Date
            2013-02-20 00:00:00
            Application Docs ID
            13348
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            14
            Submission Type
            SUPPL
          9. Appl No
            020753
            Application Docs Date
            2014-05-06 00:00:00
            Application Docs ID
            13349
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            16
            Submission Type
            SUPPL
          10. Appl No
            020753
            Application Docs Date
            2016-07-27 00:00:00
            Application Docs ID
            13350
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            18
            Submission Type
            SUPPL
          11. Appl No
            020753
            Application Docs Date
            2014-05-06 00:00:00
            Application Docs ID
            35273
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            15
            Submission Type
            SUPPL
          12. Appl No
            020753
            Application Docs Date
            2018-05-22 00:00:00
            Application Docs ID
            54284
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            20
            Submission Type
            SUPPL
          all submission records
          1. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            25
            Submission Status
            AP
            Submission Status Date
            2024-12-16 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          2. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            22
            Submission Status
            AP
            Submission Status Date
            2021-11-17 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          3. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            20
            Submission Status
            AP
            Submission Status Date
            2018-05-18 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          4. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            2
            Submission No
            18
            Submission Status
            AP
            Submission Status Date
            2016-07-25 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          5. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            4
            Submission No
            17
            Submission Status
            AP
            Submission Status Date
            2014-07-28 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          6. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            16
            Submission Status
            AP
            Submission Status Date
            2014-05-02 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          7. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            15
            Submission Status
            AP
            Submission Status Date
            2014-05-02 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          8. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            14
            Submission Status
            AP
            Submission Status Date
            2013-02-15 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          9. Appl No
            020753
            Review Priority
            UNKNOWN
            Submission Class Code ID
            3
            Submission No
            12
            Submission Status
            AP
            Submission Status Date
            2011-03-25 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          10. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            11
            Submission Status
            AP
            Submission Status Date
            2011-03-25 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          11. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            9
            Submission Status
            AP
            Submission Status Date
            2011-03-25 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          12. Appl No
            020753
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            7
            Submission Status
            AP
            Submission Status Date
            2008-12-24 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          application number
          NDA020753
          approval interpretation
          Application linkage and approved submission are not indication-level current approval verification
          current indication status
          not_reconciled
          has approved submission record
          true
          latest approved submission date
          2024-12-16
          latest label selection rule
          max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
          latest posted label documents
          1. Appl No
            020753
            Application Docs Date
            2024-12-17 00:00:00
            Application Docs ID
            80601
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            25
            Submission Type
            SUPPL
          official application record
          Appl No
          020753
          Appl Public Notes
          Appl Type
          NDA
          Sponsor Name
          PFIZER
          openfda application present
          true
          products
          1. Active Ingredient
            EXEMESTANE
            Appl No
            020753
            Drug Name
            AROMASIN
            Form
            TABLET;ORAL
            Product No
            001
            Reference Drug
            1
            Reference Standard
            1
            Strength
            25MG
            marketing status
            1. Prescription

        Source passages and status connections

        Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

        Passage 1 · indication intro context
        application numbers
        1. NDA020753
        brand names
        1. Aromasin
        classification reasons
        1. explicit_positive_indication_predicate
        2. no_tumor_directed_keyword_in_positive_statement
        3. incomplete_colon_led_indication_intro
        clinical review status
        pending
        content role
        indication_intro_context
        context span
        end
        273
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE AROMASIN is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a tot
        label id
        aacc35a2-0e82-4ba7-bec1-297802d4fa44
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
        start
        0
        current approval status
        not_reconciled
        duplicate text group
        dup-bffb420b819ea2596e3b
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. EXEMESTANE
        id
        ind-span-927ce5f43d4796fe84fc
        label id
        aacc35a2-0e82-4ba7-bec1-297802d4fa44
        positive predicate support span
        end
        68
        end exclusive
        true
        exact text
        is an aromatase inhibitor indicated
        label id
        aacc35a2-0e82-4ba7-bec1-297802d4fa44
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
        start
        33
        qualifier mentions
          regulatory links
            schema version
            0.1.0
            source batch sha256
            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
            source defined aliases
              source span
              end
              73
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE AROMASIN is an aromatase inhibitor indicated for:
              label id
              aacc35a2-0e82-4ba7-bec1-297802d4fa44
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
              start
              0
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%22aacc35a2-0e82-4ba7-bec1-297802d4fa44%22
              spl effective date
              2025-12-24
              spl set id
              cf066b7a-032a-416c-8d40-15ba581423e3
              spl version
              24
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              not_applicable
              Passage 2 · unclassified context
              application numbers
              1. NDA020753
              brand names
              1. Aromasin
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              540
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE AROMASIN is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated f
              label id
              aacc35a2-0e82-4ba7-bec1-297802d4fa44
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
              start
              0
              current approval status
              not_reconciled
              duplicate text group
              dup-0fdee8c75247f3b3362d
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. EXEMESTANE
              id
              ind-span-f6061c6c7a24bbcc4184
              label id
              aacc35a2-0e82-4ba7-bec1-297802d4fa44
              positive predicate support span
              Source null
              qualifier mentions
              1. context exact
                • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have
                kind
                stage_or_setting
                polarity
                not_inferred
                span
                end
                119
                end exclusive
                true
                exact text
                adjuvant treatment of postmenopausal women
                label id
                aacc35a2-0e82-4ba7-bec1-297802d4fa44
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                start
                76
              2. context exact
                ASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ).
                kind
                stage_or_setting
                polarity
                not_inferred
                span
                end
                335
                end exclusive
                true
                exact text
                adjuvant hormonal therapy ( 14
                label id
                aacc35a2-0e82-4ba7-bec1-297802d4fa44
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                start
                305
              3. context exact
                l women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ).
                kind
                prior_therapy_or_line
                polarity
                not_inferred
                span
                end
                335
                end exclusive
                true
                exact text
                who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14
                label id
                aacc35a2-0e82-4ba7-bec1-297802d4fa44
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                start
                171
              regulatory links
                schema version
                0.1.0
                source batch sha256
                424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                source defined aliases
                  source span
                  end
                  340
                  end exclusive
                  true
                  exact text
                  • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ).
                  label id
                  aacc35a2-0e82-4ba7-bec1-297802d4fa44
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                  start
                  74
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%22aacc35a2-0e82-4ba7-bec1-297802d4fa44%22
                  spl effective date
                  2025-12-24
                  spl set id
                  cf066b7a-032a-416c-8d40-15ba581423e3
                  spl version
                  24
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  unclear
                  Passage 3 · unclassified context
                  application numbers
                  1. NDA020753
                  brand names
                  1. Aromasin
                  classification reasons
                  1. no_unambiguous_positive_indication_predicate
                  clinical review status
                  pending
                  content role
                  unclassified_context
                  context span
                  end
                  669
                  end exclusive
                  true
                  exact text
                  positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three
                  label id
                  aacc35a2-0e82-4ba7-bec1-297802d4fa44
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                  start
                  141
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-0a9b14953333f953cd39
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. EXEMESTANE
                  id
                  ind-span-0710e1cf9d35bbed9e82
                  label id
                  aacc35a2-0e82-4ba7-bec1-297802d4fa44
                  positive predicate support span
                  Source null
                  qualifier mentions
                  1. context exact
                    • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
                    kind
                    stage_or_setting
                    polarity
                    not_inferred
                    span
                    end
                    399
                    end exclusive
                    true
                    exact text
                    advanced breast cancer in postmenopausal wo
                    label id
                    aacc35a2-0e82-4ba7-bec1-297802d4fa44
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                    start
                    356
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                    source defined aliases
                      source span
                      end
                      469
                      end exclusive
                      true
                      exact text
                      • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ).
                      label id
                      aacc35a2-0e82-4ba7-bec1-297802d4fa44
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                      start
                      341
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%22aacc35a2-0e82-4ba7-bec1-297802d4fa44%22
                      spl effective date
                      2025-12-24
                      spl set id
                      cf066b7a-032a-416c-8d40-15ba581423e3
                      spl version
                      24
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      unclear
                      Passage 4 · positive indication candidate
                      application numbers
                      1. NDA020753
                      brand names
                      1. Aromasin
                      classification reasons
                      1. explicit_positive_indication_predicate
                      2. tumor_or_malignant_hematology_words_in_positive_statement
                      clinical review status
                      pending
                      content role
                      positive_indication_candidate
                      context span
                      end
                      1029
                      end exclusive
                      true
                      exact text
                      total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). • treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ). 1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [
                      label id
                      aacc35a2-0e82-4ba7-bec1-297802d4fa44
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                      start
                      270
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-47f415c22c639e402c31
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. EXEMESTANE
                      id
                      ind-span-59e3a95bd508ef20e758
                      label id
                      aacc35a2-0e82-4ba7-bec1-297802d4fa44
                      positive predicate support span
                      end
                      538
                      end exclusive
                      true
                      exact text
                      is indicated
                      label id
                      aacc35a2-0e82-4ba7-bec1-297802d4fa44
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                      start
                      526
                      qualifier mentions
                      1. context exact
                        1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopaus
                        kind
                        stage_or_setting
                        polarity
                        not_inferred
                        span
                        end
                        517
                        end exclusive
                        true
                        exact text
                        Adjuvant Treatment of Postmenopausal Women
                        label id
                        aacc35a2-0e82-4ba7-bec1-297802d4fa44
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                        start
                        474
                      2. context exact
                        Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have
                        kind
                        stage_or_setting
                        polarity
                        not_inferred
                        span
                        end
                        586
                        end exclusive
                        true
                        exact text
                        adjuvant treatment of postmenopausal women
                        label id
                        aacc35a2-0e82-4ba7-bec1-297802d4fa44
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                        start
                        543
                      3. context exact
                        ASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ].
                        kind
                        stage_or_setting
                        polarity
                        not_inferred
                        span
                        end
                        815
                        end exclusive
                        true
                        exact text
                        adjuvant hormonal therapy [see Clinical Stu
                        label id
                        aacc35a2-0e82-4ba7-bec1-297802d4fa44
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                        start
                        772
                      4. context exact
                        l women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ].
                        kind
                        prior_therapy_or_line
                        polarity
                        not_inferred
                        span
                        end
                        815
                        end exclusive
                        true
                        exact text
                        who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Stu
                        label id
                        aacc35a2-0e82-4ba7-bec1-297802d4fa44
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                        start
                        638
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                        source defined aliases
                          source span
                          end
                          829
                          end exclusive
                          true
                          exact text
                          1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ].
                          label id
                          aacc35a2-0e82-4ba7-bec1-297802d4fa44
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                          start
                          470
                          source url
                          https://api.fda.gov/drug/label.json?search=id%3A%22aacc35a2-0e82-4ba7-bec1-297802d4fa44%22
                          spl effective date
                          2025-12-24
                          spl set id
                          cf066b7a-032a-416c-8d40-15ba581423e3
                          spl version
                          24
                          structured fields status
                          not_extracted_no_values_inferred_from_mentions
                          structured indication
                          age
                          Source null
                          approval pathway
                          Source null
                          biomarker and test
                          Source null
                          disease stage
                          Source null
                          limitations
                          Source null
                          line
                          Source null
                          prior therapy
                          Source null
                          regimen
                          Source null
                          tumor histology
                          Source null
                          use intent
                          tumor_directed_candidate
                          Passage 5 · positive indication candidate
                          application numbers
                          1. NDA020753
                          brand names
                          1. Aromasin
                          classification reasons
                          1. explicit_positive_indication_predicate
                          2. tumor_or_malignant_hematology_words_in_positive_statement
                          clinical review status
                          pending
                          content role
                          positive_indication_candidate
                          context span
                          end
                          1059
                          end exclusive
                          true
                          exact text
                          cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy [see Clinical Studies (14.1) ]. 1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
                          label id
                          aacc35a2-0e82-4ba7-bec1-297802d4fa44
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                          start
                          630
                          current approval status
                          not_reconciled
                          duplicate text group
                          dup-cb5c5ece8e14db1cc9c2
                          extraction review status
                          automated_candidate_pending_source_review
                          generic names
                          1. EXEMESTANE
                          id
                          ind-span-9cfa62c7efd975dddb63
                          label id
                          aacc35a2-0e82-4ba7-bec1-297802d4fa44
                          positive predicate support span
                          end
                          902
                          end exclusive
                          true
                          exact text
                          is indicated
                          label id
                          aacc35a2-0e82-4ba7-bec1-297802d4fa44
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                          start
                          890
                          qualifier mentions
                          1. context exact
                            1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced brea
                            kind
                            stage_or_setting
                            polarity
                            not_inferred
                            span
                            end
                            877
                            end exclusive
                            true
                            exact text
                            Advanced Breast Cancer in Postmenopausal Wo
                            label id
                            aacc35a2-0e82-4ba7-bec1-297802d4fa44
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                            start
                            834
                          2. context exact
                            menopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
                            kind
                            stage_or_setting
                            polarity
                            not_inferred
                            span
                            end
                            967
                            end exclusive
                            true
                            exact text
                            advanced breast cancer in postmenopausal wo
                            label id
                            aacc35a2-0e82-4ba7-bec1-297802d4fa44
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                            start
                            924
                          regulatory links
                            schema version
                            0.1.0
                            source batch sha256
                            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                            source defined aliases
                              source span
                              end
                              1059
                              end exclusive
                              true
                              exact text
                              1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
                              label id
                              aacc35a2-0e82-4ba7-bec1-297802d4fa44
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              286cae4dbab87fd9ab9311185c57edaa795dd25a406b88af0f442fbbc5395f82
                              start
                              830
                              source url
                              https://api.fda.gov/drug/label.json?search=id%3A%22aacc35a2-0e82-4ba7-bec1-297802d4fa44%22
                              spl effective date
                              2025-12-24
                              spl set id
                              cf066b7a-032a-416c-8d40-15ba581423e3
                              spl version
                              24
                              structured fields status
                              not_extracted_no_values_inferred_from_mentions
                              structured indication
                              age
                              Source null
                              approval pathway
                              Source null
                              biomarker and test
                              Source null
                              disease stage
                              Source null
                              limitations
                              Source null
                              line
                              Source null
                              prior therapy
                              Source null
                              regimen
                              Source null
                              tumor histology
                              Source null
                              use intent
                              tumor_directed_candidate

                              Preserved source evidence · Not medical advice